Apexian Pharmaceuticals, Inc.

20 S. Meridian Street
Suite 800
Indianapolis
Indiana
46202
United States

Tel: 844-463-3330 ext. 114

Show jobs for this employer

About Apexian Pharmaceuticals, Inc.

Apexian Pharmaceuticals is a privately held clinical-stage biotechnology company focused on developing novel compounds to treat cancer, targeting the multiple functions of the APE1 protein. Established based upon the research of our founder and CSO, Mark Kelley, Ph.D., Apexian is advancing a lead drug candidate, APX3330, ready to move into clinical studies. Apexian will initially target late stage cancers refractory to existing treatments in a multi-center phase 1 clinical study. Several additional drug candidates are in pre-clinical development that came from an extensive structure activity relationship (SAR) to build a broad intellectual property portfolio in this target area. In addition to treating cancers directly, these molecules impact other important biological function and those are being assessed through collaborations with global researchers.

8 articles with Apexian Pharmaceuticals, Inc.